3,3-bis(diisopropoxyphosphinoyl)propionic acid | 115582-63-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: 3,3-bis(diisopropoxyphosphinoyl)propionic acid
• 英文别名: tetraisopropyl 2-carboxyethane-1,1-diphosphonate；3,3-bis(diisopropoxyphosphoryl)propanoic acid；3,3-Bis(diisopropoxyphosphinyl)propionic acid；3,3-bis[di(propan-2-yloxy)phosphoryl]propanoic acid
• CAS: 115582-63-3
• 化学式: C₁₅H₃₂O₈P₂
• 分子量: 402.362
• InChiKey: OQRMFEHNEHDCAX-UHFFFAOYSA-N

物化性质

• 沸点：
  490.2±40.0 °C(predicted)
• 密度：
  1.161±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3,3-bis(diisopropoxyphosphinoyl)propionic acid 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以95%的产率得到[2-Chlorocarbonyl-1-(diisopropoxy-phosphoryl)-ethyl]-phosphonic acid diisopropyl ester
  参考文献：
  名称：

  Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis

  摘要：

  Conjugates of bisphosphonates (potential bone resorption inhibitors) and prostaglandin E-2 (a bone formation enhancer) were prepared and evaluated for their ability to bind to bone and to liberate, enzymatically, free PGE(2). The conjugate 3, an amide at C-1 of PGE(2) proved to be too stable in vivo while conjugate 6, a thioester, was too labile. Several PGE(2), C-15 ester-linked conjugates (18, 23, 24 and 31) were prepared and conjugate 23 was found to bind effectively to bone in vitro and in vivo and to liberate PGE(2) at an acceptable rate. A 4-week study in a rat model of osteoporosis showed that 23 was better tolerated and more effective as a bone growth stimulant than daily maximum tolerated doses of free PGE(2). (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00045-0
• 作为产物：
  描述：

  亚甲基二磷酸四异丙酯 在 palladium on activated charcoal 氢气 、 sodium hydride 作用下， 以 乙酸乙酯 为溶剂， 反应 2.33h， 生成 3,3-bis(diisopropoxyphosphinoyl)propionic acid
  参考文献：
  名称：

  Studies on Novel Bone Resorption Inhibitors. II. Synthesis and Pharmacological Activities of Fused Aza-heteroarylbisphosphonate Derivatives.

  摘要：

  我们合成了两个新系列的融合杂己基双膦酸盐（5、8），它们在结构上与incadronate（YM175）和相关化合物有很大不同，并利用甲状旁腺激素（PTH）诱导的大鼠高钙血症模型（PIH 模型）对它们的抗骨吸收活性进行了评估。在这些化合物中，有几种表现出比帕米膦酸钠更强的抗骨吸收活性。其中，[1-羟基-2-（咪唑并[1，2-α]吡啶-3-基）亚乙基]双膦酸（5b，minodronate）不仅在 PIH 模型中，而且在大鼠固定骨萎缩模型（DA 模型）中的活性都比帕米膦酸高出 100 倍，因此被选中用于临床开发。本文讨论了这些新系列双膦酸盐的结构-活性关系。

  DOI：

  10.1248/cpb.46.1703

文献信息

• Estrogen derivative having carriers to bone
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US05962438A1

  公开（公告）日：1999-10-05

  A novel estrogen derivative represented by the formula: ##STR1## is useful for treating or preventing diseases caused by estrogen deficiency.

  一种由以下公式表示的新型雌激素衍生物：##STR1##，可用于治疗或预防由雌激素缺乏引起的疾病。
• Labelled ascorbic acid derivatives
  申请人：——

  公开号：US20030153736A1

  公开（公告）日：2003-08-14

  Compounds of formula (I) where: X 1 is OH or SH or NH 2 or -L-Z; X 2 and X 3 are the same or different and each is H, C 1-4 alkyl, benzyl a protecting group or -L-Z, X 4 is H or C 1-4 alkyl, L is a linker comprising a chain of 0-10 atoms, Z is a group comprising a detectable moiety which comprise at least one detectable moiety are useful in the diagnosis and prognosis and radiotherapy of metastatic bone disease. 1

  公式（I）的化合物，其中：X1为OH或SH或NH2或-L-Z; X2和X3相同或不同，每个都是H，C1-4烷基，苯甲基保护基或-L-Z，X4为H或C1-4烷基，L是包含0-10个原子的链连接物，Z是包含至少一个可检测基团的基团，其中至少一个可检测基团在转移性骨疾病的诊断、预后和放射治疗中有用。
• Studies on Novel Bone Resorption Inhibitors. II. Synthesis and Pharmacological Activities of Fused Aza-heteroarylbisphosphonate Derivatives.
  作者：Makoto TAKEUCHI、Shunichi SAKAMOTO、Kousei KAWAMUKI、Hiroyuki KURIHARA、Hideaki NAKAHARA、Yasuo ISOMURA

  DOI：10.1248/cpb.46.1703

  日期：——

  Two new series of fused aza-heteroarylbisphosphonates (5, 8), which are structurally quite different from incadronate (YM175), and related compounds were synthesized and evaluated for antiresorptive activity using a parathyroid hormone (PTH)-induced hypercalcemia model in rats (PIH model). Among these compounds, several exhibited more potent antiresorptive activity than pamidronate. In particular, [1-hydroxy-2-(imidazo[1, 2-α]pyridin-3-yl)ethylidene]bisphosphonic acid (5b, minodronate) was 100-fold more potent than pamidronate in not only the PIH model, but also in an immobilization bone atrophy model in rats (DA model), and was selected for clinical development. The structure-activity relationships in these new series of bisphosphonates are discussed.

  我们合成了两个新系列的融合杂己基双膦酸盐（5、8），它们在结构上与incadronate（YM175）和相关化合物有很大不同，并利用甲状旁腺激素（PTH）诱导的大鼠高钙血症模型（PIH 模型）对它们的抗骨吸收活性进行了评估。在这些化合物中，有几种表现出比帕米膦酸钠更强的抗骨吸收活性。其中，[1-羟基-2-（咪唑并[1，2-α]吡啶-3-基）亚乙基]双膦酸（5b，minodronate）不仅在 PIH 模型中，而且在大鼠固定骨萎缩模型（DA 模型）中的活性都比帕米膦酸高出 100 倍，因此被选中用于临床开发。本文讨论了这些新系列双膦酸盐的结构-活性关系。
• NOVEL BONE-SEEKING ESTROGEN DERIVATIVE
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0827951A1

  公开（公告）日：1998-03-11

  A novel estrogen derivative represented by the formula: is useful for treating or preventing diseases caused by estrogen deficiency.

  一种由式表示的新型雌激素衍生物： 可用于治疗或预防由雌激素缺乏引起的疾病。
• LABELLED ASCORBIC ACID DERIVATIVES
  申请人：Amersham plc

  公开号：EP1239886A2

  公开（公告）日：2002-09-18